The postoperative platelet-to-lymphocyte ratio predicts the outcome of patients undergoing pancreaticoduodenectomy for pancreatic head cancer.
暂无分享,去创建一个
T. Gocho | K. Furukawa | Yoshihiro Shirai | K. Haruki | Toru Ikegami | R. Hamura | T. Sakamoto | S. Onda | Yoshiaki Tanji | T. Taniai | M. Yanagaki
[1] J. D'haese,et al. Effect of platelet inhibition with perioperative aspirin on survival in patients undergoing curative resection for pancreatic cancer: a propensity score matched analysis , 2021, BMC Surgery.
[2] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[3] M. Sekimoto,et al. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma , 2020, Surgery Today.
[4] P. Hjemdahl,et al. Increased platelet reactivity and platelet–leukocyte aggregation after elective coronary bypass surgery , 2018, Platelets.
[5] J. Manson,et al. Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies. , 2018, Gastroenterology.
[6] S. Tucker,et al. Platelets and cancer angiogenesis nexus , 2017, Cancer and Metastasis Reviews.
[7] D. Gouma,et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After , 2017, Surgery.
[8] K. Yanaga,et al. Preoperative Platelet-to-Albumin Ratio Predicts Prognosis of Patients with Pancreatic Ductal Adenocarcinoma After Pancreatic Resection. , 2017, Anticancer research.
[9] K. Soo,et al. Preoperative platelet–lymphocyte ratio is an independent prognostic marker and superior to carcinoembryonic antigen in colorectal peritoneal carcinomatosis patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy , 2017, International Journal of Clinical Oncology.
[10] D. Cameron,et al. ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours , 2016, Contemporary clinical trials.
[11] Y. Ku,et al. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios , 2016, Surgery Today.
[12] M. Ikeguchi,et al. Prognostic indicators based on inflammatory and nutritional factors after pancreaticoduodenectomy for pancreatic cancer , 2016, Surgery Today.
[13] M. Gonen,et al. Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma , 2016, Journal of surgical oncology.
[14] K. Yanaga,et al. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. , 2015, Surgery.
[15] T. Burnouf,et al. Platelets effects on tumor growth. , 2014, Seminars in oncology.
[16] J. Jacob,et al. Reduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients with pancreatic cancer. , 2014, JAMA surgery.
[17] Masaya Suenaga,et al. Modified Blumgart Anastomosis for Pancreaticojejunostomy: Technical Improvement in Matched Historical Control Study , 2014, Journal of Gastrointestinal Surgery.
[18] D. Quail,et al. Microenvironmental regulation of tumor progression and metastasis , 2013, Nature Medicine.
[19] A. Hinke,et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. , 2013, JAMA.
[20] M. Ishikawa,et al. Perioperative immune responses in cancer patients undergoing digestive surgeries , 2009, World journal of surgical oncology.
[21] N. Demartines,et al. Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.
[22] A. Ordinas,et al. Tumor‐cell‐induced platelet aggregation is a glycoprotein‐dependent and lipoxygenase‐associated process , 1987, International Journal of Cancer.
[23] J. Harmon,et al. Metastasis-promoting role of extravasated platelet activation in tumor. , 2015, The Journal of surgical research.